×
About 178 results

ALLMedicine™ Fungal Pneumonia Center

Research & Reviews  54 results

Invasive Fungal Pneumonia in Immunocompromised Patients.
https://doi.org/10.1016/j.rcl.2022.01.006
Radiologic Clinics of North America; Godoy MCB, Ferreira Dalla Pria HR et. al.

May 10th, 2022 - Fungal pneumonia is the most frequent presentation of invasive fungal infections (IFIs) in patients with hematologic malignancies (HM) and hematopoietic stem cell transplantation (HSCT) recipients. The most common causes include Aspergillus, Mucor...

PC945 Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT05037851

May 4th, 2022 - Part 1 of the study comprises a 12 week Prophylaxis or Pre-emptive Therapy Phase. Part 2 comprises a 4-week Safety Follow-Up Phase. The study will screen single or double lung transplant recipients due to receive a mold-active antifungal: either a...

Opportunistic pneumonia caused by E. cuniculi in mice immunosuppressed with cyclophosph...
https://doi.org/10.1016/j.imbio.2022.152194
Immunobiology Figuerêdo Moreira I, Marcelino Alvares-Saraiva A et. al.

Mar 13th, 2022 - Opportunistic fungal pneumonia is a cause of concern in immunocompromised patients due to its high morbidity and mortality rates. One such opportunistic agent affecting immunocompromised patients is the microsporidia called Encephalitozoon cunicul...

Aspiration Pneumonitis and Pneumonia
https://emedicine.medscape.com/article/296198-overview

Oct 12th, 2021 - Overview of Aspiration Pneumonia Aspiration is defined as the inhalation of either oropharyngeal or gastric contents into the lower airways, that is, the act of taking foreign material into the lungs. This can cause a number of syndromes determine...

Aspiration Pneumonitis and Pneumonia
https://emedicine.medscape.com/article/296198-print

Oct 12th, 2021 - Aspiration is defined as the inhalation of either oropharyngeal or gastric contents into the lower airways, that is, the act of taking foreign material into the lungs. This can cause a number of syndromes determined by the quantity and nature of t...

see more →

Clinicaltrials.gov  2 results

PC945 Prophylaxis or Pre-emptive Therapy Against Pulmonary Aspergillosis in Lung Transplant Recipients
https://clinicaltrials.gov/ct2/show/NCT05037851

May 4th, 2022 - Part 1 of the study comprises a 12 week Prophylaxis or Pre-emptive Therapy Phase. Part 2 comprises a 4-week Safety Follow-Up Phase. The study will screen single or double lung transplant recipients due to receive a mold-active antifungal: either a...

fungalAi for Fungal Surveillance & Antifungal Stewardship
https://clinicaltrials.gov/ct2/show/NCT03793231

Oct 23rd, 2020 - Invasive fungal diseases (IFD) are rare infections that cause a life-threatening pneumonia in patients with weakened immune systems usually due to cancer chemotherapy and transplantation. Fungal spores are found in air, water and soil making expos...

see more →

News  13 results

FDA Approves Brexucabtagene Autoleucel for Relapsed/Refractory B-ALL
https://www.onclive.com/view/fda-approves-brexucabtagene-autoleucel-for-relapsed-refractory-b-all

Oct 8th, 2021 - The FDA has approved brexucabtagene autoleucel (Tecartus; formerly KTE-X19) as a treatment for adult patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia (B-ALL).1 The regulatory decision was based on findings from the ...

FDA Grants CAR T-cell Therapy ALLO-715 Orphan Drug Status for Multiple Myeloma
https://www.onclive.com/view/fda-grants-car-t-cell-therapy-allo-715-orphan-drug-status-for-multiple-myeloma

Aug 17th, 2021 - The FDA has granted an orphan drug designation to the allogeneic CAR T-cell therapy ALLO-715 for the treatment of patients with multiple myeloma, according to an announcement from Allogene Therapeutics, Inc., the drug developer.1 Data from the ...

Brexucabtagene Autoleucel Induces High, Durable Responses in Heavily Pretreated Relapsed/Refractory B-ALL
https://www.onclive.com/view/kte-x19-induces-high-durable-response-rate-in-heavily-pretreated-relapsed-refractory-b-all

Jun 5th, 2021 - A single infusion of brexucabtagene autoleucel (formerly KTE-X19; Tecartus), a CAR T-cell therapy, demonstrated robust and durable responses in heavily pretreated patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL), accor...

FDA Grants RMAT Designation to ALLO-715 for Relapsed/Refractory Multiple Myeloma
https://www.onclive.com/view/fda-grants-rmat-designation-to-allo-715-for-relapsed-refractory-multiple-myeloma

Apr 21st, 2021 - The FDA granted a Regenerative Medicine Advanced Therapy (RMAT) designation to the allogeneic chimeric antigen receptor (CAR) T-cell therapy as a potential treatment for patients with relapsed/refractory multiple myeloma, according to Allogene The...

The Importance of Supportive Care in AML
https://www.onclive.com/view/the-importance-of-supportive-care-in-aml

Apr 2nd, 2021 - Transcript:Ruben A. Mesa, MD, FACP: Elias, you brought up earlier an excellent point and a segue into our last key section on the issue of support infection and all other aspects. And we’ve had a good discussion regarding how there’s been signific...

see more →

Patient Education  2 results see all →